BIOMAT Database Logo BIOMAT Database Logo

[Indications and limits of ablative therapies in prostate cancer]. 2017

R Sanchez-Salas, and E Barret, and R Renard-Penna, and J-M Cosset, and P Dell'Oglio, and J Battista, and A Gangi, and H Lang, and X Cathelineau
Département d'urologie, institut mutualiste Montsouris, 42, boulevard Jourdan, 75014 Paris, France; Université Paris Descartes, 75006 Paris, France.

OBJECTIVE To perform a state of the art about indications and limits of ablative therapies for localized prostate cancer. METHODS A review of the scientific literature was performed in Medline database (http://www.ncbi.nlm.nih.gov) and Embase (http://www.embase.com) using different associations of keywords. Publications obtained were selected based on methodology, language and relevance. After selection, 107 articles were analysed. RESULTS The objective to combine reduction of side effects and oncological control has induced recent development of several ablative therapies. Beyond this heterogeneity, some preferential indications appear: unilateral cancer of low risk (but with significant volume, excluding active surveillance) or intermediate risk (excluding majority of grade 4); treatment targeted the index lesion, by quarter or hemi-ablation, based on biopsy and mpMRI. In addition, indications must considered specific limits of each energy, such as gland volume and tumor localization. CONCLUSIONS Based on new imaging and biopsy, ablative therapies will probably increased its role in the future in management of localize prostate cancer. The multiple ongoing trials will certainly be helpful to better define their indications and limits.

UI MeSH Term Description Entries
D008297 Male Males
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000066491 Clinical Decision-Making Process of formulating a diagnosis based on medical history and physical or mental examinations, and/or choosing an appropriate intervention. Medical Decision-Making,Clinical Decision Making,Decision-Making, Clinical,Decision-Making, Medical,Medical Decision Making
D055011 Ablation Techniques Removal of tissue by vaporization, abrasion, or destruction. Methods used include heating tissue by hot liquids or microwave thermal heating, freezing (CRYOABLATION), chemical ablation, and photoablation with LASERS. Ablation Technique,Technique, Ablation,Techniques, Ablation

Related Publications

R Sanchez-Salas, and E Barret, and R Renard-Penna, and J-M Cosset, and P Dell'Oglio, and J Battista, and A Gangi, and H Lang, and X Cathelineau
Targeted Ablative Therapies for Prostate Cancer.
January 2018, Cancer treatment and research,
R Sanchez-Salas, and E Barret, and R Renard-Penna, and J-M Cosset, and P Dell'Oglio, and J Battista, and A Gangi, and H Lang, and X Cathelineau
Minimally invasive ablative therapies for the treatment of prostate cancer.
January 2011, Reviews in urology,
R Sanchez-Salas, and E Barret, and R Renard-Penna, and J-M Cosset, and P Dell'Oglio, and J Battista, and A Gangi, and H Lang, and X Cathelineau
Misinformation on the Internet regarding Ablative Therapies for Prostate Cancer.
November 2019, Urology,
R Sanchez-Salas, and E Barret, and R Renard-Penna, and J-M Cosset, and P Dell'Oglio, and J Battista, and A Gangi, and H Lang, and X Cathelineau
[Ablative therapy in kidney cancer: Indications].
November 2017, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie,
R Sanchez-Salas, and E Barret, and R Renard-Penna, and J-M Cosset, and P Dell'Oglio, and J Battista, and A Gangi, and H Lang, and X Cathelineau
Complications of ablative therapies in lung cancer.
March 2008, Clinical lung cancer,
R Sanchez-Salas, and E Barret, and R Renard-Penna, and J-M Cosset, and P Dell'Oglio, and J Battista, and A Gangi, and H Lang, and X Cathelineau
Proximity of prostate cancer to the urethra: implications for minimally invasive ablative therapies.
November 2000, Urology,
R Sanchez-Salas, and E Barret, and R Renard-Penna, and J-M Cosset, and P Dell'Oglio, and J Battista, and A Gangi, and H Lang, and X Cathelineau
Ablative Therapies in Low-Risk Thyroid Cancer.
May 2025, Annals of surgical oncology,
R Sanchez-Salas, and E Barret, and R Renard-Penna, and J-M Cosset, and P Dell'Oglio, and J Battista, and A Gangi, and H Lang, and X Cathelineau
Minimally invasive ablative therapies for definitive treatment of localized prostate cancer in the primary setting.
January 2011, Prostate cancer,
R Sanchez-Salas, and E Barret, and R Renard-Penna, and J-M Cosset, and P Dell'Oglio, and J Battista, and A Gangi, and H Lang, and X Cathelineau
Oligometastases in prostate cancer: Ablative treatment.
February 2019, World journal of clinical oncology,
R Sanchez-Salas, and E Barret, and R Renard-Penna, and J-M Cosset, and P Dell'Oglio, and J Battista, and A Gangi, and H Lang, and X Cathelineau
Kidney cancer ablative therapy: indications and patient selection.
January 2008, Current urology reports,
Copied contents to your clipboard!